Has successfully prepared a Covid-19 vaccine with ‘100% protection’ | World

12/27/2020 World



[ad_1]

The AFP news agency reported on December 27 that AstraZeneca and the University of Oxford in the United Kingdom had a “winning formula” for the effectiveness of the Covid-19 vaccine that was being evaluated by the authorities of this country.

AstraZeneca CEO Pascal Soriot said the vaccine offers “100% protection” against serious illnesses that require hospitalization. He believes the trial will show that the company’s vaccines are as effective as the US-German joint venture Pfizer-BioNTech (95%) and Moderna (94.5%).

“We think we have identified a winning formula,” he said, adding that the vaccine will also have two doses.

90% of the population is vaccinated with Covid-19, the United States only has community immunity.

Earlier, on December 23, the British government announced that the Oxford-AstraZeneca vaccine data had been submitted to the British Medicines and Medicines Administration (MHRA).

Bed sheet Sunday Telegraph The vaccine is expected to be certified on December 28. Prior to that, the Pfizer-BioNTech vaccine was the first Covid-19 vaccine licensed in the UK and has administered to approximately 600,000 people in the high-risk group.
Initial trials showing mixed results on vaccine efficacy, researched and produced by Oxford-AstraZeneca. The mean initial efficacy was 70% but increased to 90% depending on the dose.

Large trials in the UK and Brazil show that the vaccine is 62% effective in people receiving the 2 full doses. However, volunteers injected half a dose before and 1 dose after 1 month showed an efficacy of 90%.

The Oxford-AstraZeneca vaccine has the Pfizer-BioNTech advantage in that it can be stored in normal cold, 2 to 8.0C for 6 months. Meanwhile, the Pfizer-BioNTech vaccine should be stored at -700C.




[ad_2]

Designed by Tricksfast Solutions
© Copyright 2024, All Rights Reserved